Synlogic (SYBX) AI Stock Analysis

• Market Cap: $7.25M
• Dividend Yield: N/A
• Average Volume (3M): 41.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -100.00%
• EPS Growth: 93.62%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,698,919
• 10 Day Avg. Volume: 24,108
• 30 Day Avg. Volume: 41,078
• PEG Ratio: <0.01
• Price to Book (P/B): 1.34
• Price to Sales (P/S): 2134.34
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: -1.15
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 3.85
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.53 ▼(-56.39% Downside)
• Action: Downgraded Date: 01/21/26
• Date: Action: Downgraded 01/21/26

The score is weighed down primarily by weak financial performance (zero revenue, ongoing losses and negative cash flow) and very bearish technicals (price far below key moving averages with negative MACD). A Nasdaq delisting/OTC transition adds significant event-driven risk, while valuation is constrained by continued losses and no dividend support.

Positive Factors

Strong Equity Base

A strong equity base without debt provides Synlogic with financial stability and flexibility, allowing it to invest in R&D and strategic initiatives without the burden of interest payments.

High Revenue Growth

High revenue growth indicates increasing demand for Synlogic's products, suggesting successful R&D efforts and potential market expansion, crucial for long-term success in biotechnology.

Strategic Partnerships

Strategic partnerships provide Synlogic with milestone payments and research funding, enhancing its R&D capabilities and accelerating the development of its Synthetic Biotic medicines.

Negative Factors

Persistent Losses

Ongoing losses highlight operational inefficiencies and high costs, which could hinder Synlogic's ability to achieve sustainable profitability and limit its financial resources for growth.

Negative Cash Flows

Negative cash flows indicate cash consumption in operations, necessitating strategic cash management to ensure liquidity and fund ongoing R&D and operational activities.

Decreasing Total Assets

A decline in total assets could limit Synlogic's ability to invest in new projects and maintain competitive advantage, potentially impacting long-term growth and market position.

Synlogic Business Overview & Revenue Model

Company Description

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Synlogic makes money primarily through the development and potential commercialization of its Synthetic Biotic medicines. The company is engaged in partnerships and collaborations with other biotechnology and pharmaceutical firms to advance its research and development efforts, which can provide milestone payments and research funding. Additionally, Synlogic aims to generate revenue through licensing agreements and eventual sales of its therapeutic products upon successful clinical trials and regulatory approvals.

Synlogic Financial Statement Overview

Summary

Financials indicate a high-risk, cash-consuming profile: TTM revenue is $0 with ongoing net losses and negative operating/free cash flow (~-$4.0M). While burn has improved versus prior years and there is no debt, the steep decline in equity and assets limits flexibility and underscores reliance on external funding.

Income Statement

SYBX shows a persistent lack of operating scale and profitability. TTM (Trailing-Twelve-Months) revenue is $0 versus $8k in 2024 and $3.37M in 2023, indicating a sharp contraction and limited commercialization. Losses remain meaningful despite improvement in TTM (net loss of ~$3.2M vs. ~$23.4M in 2024 and ~$57.3M in 2023), suggesting cost reduction but not a durable earnings model yet. Overall, the trajectory reflects ongoing operating deficits and high dependence on external funding rather than self-sustaining operations.

Balance Sheet

The balance sheet is mixed but has a key strength: debt is currently $0 in TTM (Trailing-Twelve-Months) and 2024, which reduces financial risk and interest burden. However, equity has fallen materially (from ~$147.3M in 2021 to ~$12.8M in 2024 and ~$10.3M in TTM), consistent with cumulative losses and/or dilution, and returns on equity are deeply negative (TTM ~-26%, 2024 ~-183%). Assets have also declined substantially (to ~$16.6M TTM from ~$174.7M in 2021), limiting financial flexibility.

Cash Flow

Cash generation remains weak: TTM (Trailing-Twelve-Months) operating cash flow and free cash flow are both about -$4.0M, following very large cash outflows in prior years (e.g., operating cash flow of about -$31.7M in 2024 and -$51.6M in 2023). The reduced burn rate is a positive signal, but cash flow still does not cover the business’s needs without financing. Free cash flow has generally tracked net income closely (roughly 1x in multiple periods), indicating losses are translating into cash outflows rather than being mainly accounting-driven.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	8.00K	3.37M	1.18M	1.75M	545.00K
Gross Profit	0.00	8.00K	3.37M	1.18M	1.75M	545.00K
EBITDA	-2.17M	-22.06M	-55.31M	-63.63M	-58.12M	-56.53M
Net Income	-3.23M	-23.36M	-57.28M	-66.15M	-60.56M	-59.17M
Balance Sheet
Total Assets	16.55M	19.83M	75.55M	110.86M	174.74M	143.84M
Cash, Cash Equivalents and Short-Term Investments	15.59M	18.86M	47.75M	77.63M	128.59M	100.44M
Total Debt	0.00	0.00	17.27M	20.30M	20.59M	22.81M
Total Liabilities	6.23M	7.08M	32.90M	28.25M	27.47M	28.70M
Stockholders Equity	10.32M	12.75M	42.66M	82.61M	147.27M	115.14M
Cash Flow
Free Cash Flow	-4.00M	-31.67M	-51.83M	-57.62M	-52.88M	-39.95M
Operating Cash Flow	-4.00M	-31.66M	-51.61M	-56.89M	-52.20M	-39.55M
Investing Cash Flow	197.00K	25.34M	38.77M	58.35M	-53.25M	32.48M
Financing Cash Flow	9.00K	172.00K	20.94M	-2.04M	89.38M	13.39M

Synlogic Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYBX, the sentiment is Negative. The current price of 1.22 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.86, and below the 200-day MA of 1.30, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 33.76 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYBX.

Synlogic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LSTA	52 Neutral	$36.17M	-1.93	-71.45%	―	―	15.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CING	50 Neutral	$48.52M	-1.19	-284.50%	―	―	93.84%
ICU	44 Neutral	$10.49M	-0.19	-290.37%	―	1195.59%	87.66%
APVO	43 Neutral	$7.30M	>-0.01	-256.30%	―	―	99.02%
SYBX	40 Underperform	$7.25M	-2.34	-27.54%	―	-100.00%	93.62%
ALLR	40 Underperform	$15.60M	-0.60	-122.61%	―	―	99.82%

Synlogic Corporate Events

Synlogic to Delist from Nasdaq and Move to OTC

On November 21, 2025, Synlogic received a notice from Nasdaq’s Listing Qualifications Department stating that, based on its review of the company’s public disclosures, it believed Synlogic had become a public shell and that continued listing of its securities was no longer warranted, with a suspension and delisting targeted for December 2, 2025 unless the company requested a hearing. Synlogic requested such a hearing on November 28, 2025, temporarily staying any suspension, but after further consideration withdrew its hearing request on January 16, 2026, leading Nasdaq that same day to notify the company that trading in its shares will be suspended at the open of business on January 21, 2026 and that a delisting filing with the SEC will follow. Synlogic plans for its common stock to be quoted on the OTC Markets following the Nasdaq delisting, and it will remain an SEC-reporting company, with the transition expected not to affect its underlying business operations, though it shifts its market presence from a national exchange to an over-the-counter platform.

The most recent analyst rating on (SYBX) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Synlogic stock, see the SYBX Stock Forecast page.

Synlogic Holds Annual Meeting, Elects Directors

On December 15, 2025, Synlogic held its Annual Meeting where 87.97% of the outstanding shares were represented. During the meeting, James Flynn and Richard P. Shea were reelected as Class I directors, the executive compensation was approved, the 2025 Equity Incentive Plan was adopted, and KPMG LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025.

Synlogic Challenges Nasdaq Delisting Notice

On November 21, 2025, Synlogic, Inc. received a notice from the Nasdaq Stock Market’s Listing Qualifications Department, which expressed concerns about the company being a ‘public shell’ due to its lack of revenue-generating assets and reduced operations since February 2024. The notice highlighted the absence of revenue in 2025 and minimal research and development expenses, suggesting that the company’s securities should no longer be listed. Synlogic disagrees with this assessment and plans to request a hearing to contest the decision, although the outcome remains uncertain.